Eli Lilly and Company (LLY)
Eli Lilly and Company (LLY) Q2 2026 Earnings Call Transcript
Eli Lilly and Company (LLY) Q2 2026 Earnings Call Transcript
Market Close: Stock Rally Fades, Job Growth Weakens, Strong Earnings Boost Eli Lilly 8-5-2026
CNBC Business News Update with Peter Schacknow - Markets & Business News With Expert Analysis From Top Business Names. Visit CNBC.com For More.
Eli Lilly's Weight-Loss Drug Demand Is Nearly Limitless. Here's What Comes Next for the $1 Trillion Drugmaker
Eli Lilly (NYSE:LLY | LLY Price Prediction) opened Wednesday's session with a blowout second-quarter earnings report, sending shares sharply higher and cementing the drugmaker's status as the only pharmaceutical company trading above a $1 trillion market cap.
Lilly (LLY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Eli Lilly shares rise on revenue beat, raised outlook
Eli Lilly and Co (NYSE:LLY) shares rose nearly 7% in early trading Wednesday after the drugmaker reported second quarter results that topped Wall Street revenue expectations and raised its full-year 2026 revenue outlook, with strong demand for its Mounjaro and Zepbound weight-loss and diabetes treatments driving a sharp increase in sales. Lilly reported second quarter revenue of $22.97 billion, up 48% from $15.56 billion a year earlier and above Wall Street estimates of roughly $20.6 billion.
Eli Lilly (LLY) Q2 Earnings and Revenues Surpass Estimates
Eli Lilly (LLY) came out with quarterly earnings of $8.38 per share, beating the Zacks Consensus Estimate of $6.01 per share. This compares to earnings of $6.31 per share a year ago.
Here's How Much Traders See Eli Lilly Stock Moving After Earnings
Eli Lilly is scheduled to report earnings Wednesday morning, with traders expecting the drugmaker's stock could potentially approach last month's highs following the results.
Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings
Novo Nordisk (NYSE: NVO | NVO Price Prediction) and Eli Lilly (NYSE: LLY) both posted Q1 FY2026 results this spring, and the gap between them keeps widening.
Novo Nordisk Wipes Out $30 Billion In Market Value After Failed Heart Drug Trial
$30.7 billion. That's how much was cut from Novo Nordisk's market capitalization as of Friday's share price, lowering from $229.2 billion to $198.5 billion, marking a nearly 69% decline since hitting an all-time high of $635.7 billion in June 2024.
Lilly (LLY) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Lilly (LLY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Week Ahead: Jobs Data, Top 10 Earnings Reports to Watch
Next week keeps up the earnings barrage, a heavy dose of earnings from some of the market's largest companies, led by pharma giant Eli Lilly (LLY) and industrial bellwether Caterpillar (CAT).
